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ABSTRACT
Latent tuberculosis infection (LTBI) and human immunodeﬁ ciency virus (HIV)-coinfection are challenges in the control of 
tuberculosis transmission. We aimed to assess and summarize evidence available in the literature regarding the treatment of 
LTBI in both the general and HIV-positive population, in order to support decision making by the Brazilian Tuberculosis Control 
Program for LTBI chemoprophylaxis. We searched MEDLINE, Cochrane Library, Centre for Reviews and Dissemination, 
Embase, LILACS, SciELO, Trip database, National Guideline Clearinghouse, and the Brazilian Theses Repository to identify 
systematic reviews, randomized clinical trials, clinical guidelines, evidence-based synopses, reports of health technology 
assessment agencies, and theses that investigated rifapentine and isoniazid combination compared to isoniazid monotherapy. We 
assessed the quality of evidence from randomized clinical trials using the Jadad Scale and recommendations from other evidence 
sources using the Grading of Recommendations, Assessment, Development, and Evaluations approach. The available evidence 
suggests that there are no differences between rifapentine + isoniazid short-course treatment and the standard 6-month isoniazid 
therapy in reducing active tuberculosis incidence or death. Adherence was better with directly observed rifapentine therapy 
compared to self-administered isoniazid. The quality of evidence obtained was moderate, and on the basis of this evidence, 
rifapentine is recommended by one guideline. Available evidence assessment considering the perspective of higher adherence 
rates, lower costs, and local peculiarity context might support rifapentine use for LTBI in the general or HIV-positive populations. 
Since novel trials are ongoing, further studies should include patients on antiretroviral therapy.
Keywords: Latent tuberculosis. Evidence-based practice. Decision making.
Tuberculosis (TB) is a pronounced public health problem 
worldwide(1). Unlike the active disease, latent tuberculosis 
infection (LTBI) is a manifestation wherein bacilli have low 
metabolic activity, and hence, affected patients do not show 
any obvious symptom or etiologic agent signs in sputum 
despite a positive tuberculin test(2). Around one-third of the 
global population is currently infected by latent TB bacilli(1) (3). 
Bacilli dormancy and human immunodeﬁ ciency virus (HIV) 
coinfection are responsible for the persistence of TB as a public 
health problem(1). Hence, control measures are needed to control 
TB transmission and LTBI development into active disease.
To control the spread of TB, the Brazilian Ministry of 
Health and the World Health Organization (WHO) currently 
recommend isoniazid monotherapy for LTBI treatment 
(also known as secondary chemoprophylaxis)(4) (5). In Brazil, the 
National Tuberculosis Control Program [Programa Nacional de 
Controle da Tuberculose (PNCT)] recommends isoniazid for at 
least 6 months for both the general population and HIV-positive 
adults and adolescents(3) (5).
Although isoniazid monotherapy is used for LBTI 
treatment, the efﬁ cacy of rifamycins (e.g., rifapentine), their 
low cost, and concerns about adherence and isoniazid-induced 
hepatitis led researchers to investigate the use of rifamycins 
in monotherapy or combination therapy with others anti-
TB drugs. Recently, a 3-month course of isoniazid-rifapentine 
combination therapy was reported, which was one of the 
shortest course regimens thus far(3) (6). However, rifapentine 
has not been approved for this use in Brazil(7).
Considering the emerging therapeutic alternatives to 
isoniazid monotherapy, the present study aimed to assess 
and to synthetize evidence on the effectiveness and safety 
of rifapentine-isoniazid combination therapy in LTBI 
chemoprophylaxis in the general and HIV-positive population 
to support national recommendations for TB control.
INTRODUCTION
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This study is a summary of evidence that comprehends 
systematic literature search, studies selection, quality of 
evidence assessment, and data extraction of effectiveness and 
safety of rifapentine-isoniazid combination therapy compared 
to LTBI isoniazid monotherapy in the general and HIV-
positive population. International recommendations for LTBI 
chemoprophylaxis were also evaluated. In case of missing data, 
the authors of the respective studies were contacted.
Literature search - in April 2014, a systematic research was 
conducted, including systematic reviews, randomized controlled 
trials (RCT), clinical guidelines, reports of health technology 
assessment agencies, evidence-based synopses and theses 
that could update the Brazilian recommendations for LTBI 
chemoprophylaxis published in 2011(5). A sensible research strategy 
was applied using the terms rifapentine and latent tuberculosis in 
MEDLINE (via PubMed), Cochrane Library (via www.bvs.br), 
Centre for Reviews and Dissemination (CRD), Embase, LILACS, 
SciELO, Trip database, National Guideline Clearinghouse (NGC), 
and Brazilian Theses Repository. Study type ﬁ lters were activated, 
and no restrictions were placed on languages or publication dates. 
Studies selection - the search aimed to identify systematic 
reviews or RCT, both of which are considered high-quality 
methodological studies. Systematic reviews and RCT were 
eligible if the assessed effectiveness and safety of isoniazid and 
rifapentine combination were compared to those of isoniazid 
monotherapies in the general population with LTBI, including 
co-infected and diagnosed individuals with HIV. Other clinical 
trials designs, patients with active TB, comparisons not based 
on isoniazid, and pharmacokinetic studies were ineligible.
In addition to effectiveness studies, clinical guidelines, 
reports of health technology-assessment agencies, evidence-
based synopses and theses were selected to discuss the inclusion 
of rifapentine in international treatment protocols. One author 
(JSV) selected the studies after reading the titles and abstracts. 
Data on the effectiveness and safety of rifapentine + isoniazid 
combination therapy were peer reviewed to conﬁ rm the ﬁ ndings.
Analysis of eligible studies - study quality was assessed using 
the criterion proposed by Jadad(8) for RCT and the Grading of 
Recommendations, Assessment, Development and Evaluations 
(GRADE) approach for other sources of information(9). This 
analysis allowed classification of information reliability and 
recommendation implications. Data on the effectiveness and safety 
of rifapentine + isoniazid combination therapy are shown below.
Four hundred studies were found through the literature 
search. In total, 10 studies were included (Figure 1): 1 
systematic review(10), 2 randomized controlled trials(11) (12), 1 
American evidence-based synopsis(13), and 6 clinical guidelines 
from different settings – United States of America(14) (15), 
United Kingdom(16) (17), Australia(18), and WHO(4). The results of 
FIGURE 1 - Search results and selection of articles. 
LILACS: Literatura Latino-Americana e do Caribe em Ciências 
da Saúde (Literature in the Health Sciences in Latin America 
and the Caribbean, in Portuguese language); SciELO: Scientiﬁ c 
Electronic Library Online; NGC: National Guideline Clearinghouse; 
CRD: Centre for Reviews and Dissemination.
Studies found through database search (n = 400)
MEDLINE = 27 LILACS = 257 Embase = 29
Cochrane = 31 SciELO = 10 NGC = 22
CRD = 4 Tripdatabase = 19 Theses Repository = 1
Excluded studies (n = 386)
Studies identified after review of titles
and abstracts (n = 14)
Ineligible studies (n = 4)
Duplicates = 3
Type of study = 1
Eligible studies (n = 10)
Systematic review = 1
Randomized clinical trial = 2
Clinical guidelines = 6
Evidence- based synopsis = 1
METHODS
RESULTS
the quality-of-evidence assessment of the systematic review, 
evidence-based synopsis, and 3 clinical guidelines that considered 
the use of rifapentine are shown in Table 1.
Both the RCTs included deﬁ ned antiretroviral therapy as an 
exclusion criterion. Martinson et al.(11) designed an open-label 
RCT, but properly described randomization since the algorithm 
was computer generated. Follow-up losses were not clear; 
it was possible to identify how many subjects withdrew consent, 
but not the number of subjects who completed the follow-up 
time. Nevertheless, the primary endpoint statistical analysis was 
based on intention-to-treat analysis. When consulted, the authors 
conﬁ rmed that randomization concealment was maintained. 
Sterling et al.(12) designed an open-label non-inferiority 
RCT. It was a well-conducted cluster randomization, and its 
supplementary appendix clearly described the randomization 
and losses to follow-up. However, the study did not mention 
if there was randomization concealment. Further, it was not a 
blinded study, and the preference of the per-protocol analysis 
for efﬁ cacy endpoints instead of the intention-to-treat analysis 
may have presented a methodological limitation. 
The systematic review by Sharma et al.(10) evaluated the 
effects of rifamycins (rifampin, rifabutin, and rifapentine) 
compared to isoniazid in HIV-negative patients at high risk 
of developing active TB. This study was selected as available 
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rifapentine is limited 
and the potential for 
adverse events should 
be monitored 





rifampin, or rifapentine 
are as effective as 
isoniazid, but with 
higher rates of toxicity 








No No No Low 
CDC, 
2012(13) 
Rifapentine + isoniazid 
(max. 900mg each) 
once a week for 3 
months under DOT 
3 RCT Presentf No No Yesd Yesg  No No No Moderate 
USA, 
2012a(14) 
Does not recommend 
rifapentine + isoniazid 
for 3 months: risk of 
interaction with ART 
1 RCT Presente No No No No No No No Low 
USA, 
2012b(15) 
Does not recommend 
rifapentine + isoniazid 
for patients aged < 2 
years and children on 
ART 
3 RCT Presente No No Yesd  Yesg  No No No Moderate 
TABLE 1 - Quality-of-evidence assessment for rifapentine chemoprophylaxis in LTBI from a systematic review, evidence-based 
synopsis, and clinical guidelines, adapted from GRADE.
LTBI: latent tuberculosis infection; GRADE: Grading of Recommendations, Assessment, Development and Evaluations; RCT: randomized controlled trials; 
WHO: World Health Organization; CDC: Centers for Disease Control and Prevention; DOT: directly observed therapy; USA: United States of America; 
ART: antiretroviral therapy. aOpen-label, not blinded, not all properly randomized or analyzed by intention to treat; bAccording to the authors, these were based 
on 8 studies comparing isoniazid monotherapy to other regimens (with pyrazinamide, rifampin, and rifapentine), but such studies are not speciﬁ ed; cDespite 
applying the GRADE approach, it was not possible to identify the studies and check the performed quality assessment; dAs these studies have not been identiﬁ ed, 
we cannot afﬁ rm that ﬁ nding; eLarge conﬁ dence interval; fStudies were open-label, not blinded, and not all were properly randomized or analyzed by intention 
to treat; gThe exclusive availability of small studies may indicate a high risk of publication bias.
evidence for the efﬁ cacy and safety of rifapentine in the general 
population. For rifapentine, speciﬁ cally, the authors described 
the results of the RCT by Sterling et al.(12). The characteristics 
and results of this systematic review and the two RCTs are 
shown in Table 2.
Effectiveness - In the study by Martinson et al.(11), the proposed 
regimen of 3 months of rifapentine (900mg) + isoniazid (900mg) 
combination administered once a week under directly observed 
therapy (DOT) did not reduce TB incidence or mortality in 
adults with LTBI and HIV compared to the actual standard 
regimen of 6 months of isoniazid (300mg) self-administered 
daily. Similar to the rifapentine + isoniazid combination, 
others proposed regimens for LTBI chemoprophylaxis were 
not superior to isoniazid 6-month monotherapy in reducing TB 
or death incidences [rifamycin + isoniazid for 3 months: relative 
ratio (RR) = 0.80, 95% conﬁ dence interval (CI): 0.50-1.29, 
p = 0.34 and isoniazid monotherapy for up to 6 years: 
RR = 0.75, 95% CI: 0.38-1.38, p = 0.34].
In the RCT by Sterling et al.(12), LTBI chemoprophylaxis with 
3 months of rifapentine (900mg) + isoniazid (900mg) combination 
therapy administered once a week under DOT is at least non-
inferior to preventive treatment with 9 month isoniazid (300mg) 
self-administered daily for TB activation. It is noteworthy that 
this ﬁ nding refers to not only HIV-positive individuals, but also 
a population at high risk of progression to active TB. 
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Both studies showed that adherence was higher in 
participants who received the combination of rifapentine + 
isoniazid, which was administered by DOT(11) (12).
Safety - Martinson et al.(11) reported that severe adverse 
events were less frequent with rifamycins like rifapentine, 
compared to the control (6 months with isoniazid), but this 
difference was not signiﬁ cant. Similarly, no difference was 
observed between the rifamycins and control groups in terms 
of increasing the levels of liver transaminases(11).
In contrast, Sterling et al.(12) reported beneﬁ ts of the rifapentine 
+ isoniazid combination, as the incidence of hepatotoxicity 
was lower than that with isoniazid monotherapy for 9 
months. However, the addition of rifapentine was associated 
with a higher rate of treatment discontinuation due to adverse 
events, particularly hypersensitivity. No differences were 
observed in mortality (p = 0.22) and grade 3 (p = 0.24) and 
4 (p = 0.32) adverse events(12), as deﬁ ned by the National Cancer 
Institute (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE). 
TABLE 2 - Characteristics and results of the systematic review and both RCTs included in this summary of evidence.















RCT (South Africa) 
 
n = 1,150 
 
HIV-positive adults with LTBI  
 
33 months of follow-up 
 
 Rifapentine+isoniazid DOT for 
12 weeks (RPT+H) 1x/week 
 Rifamicin+isoniazid DOT for  
12 weeks (RIF+H) 2x/week 
 Isoniazid self-administered up to 
6 years (6yH) 1x/day 
 Isoniazid self-administered for  
6 months (6mH) 1x/day 
TB cases  
RPT+H versus 6mH 
RR = 1.05 [95% CI: 0.56–1.97]; p = 0.87 
Death cases 
RPT+H versus 6mH 
RR = 0.66 [95% CI: 0.33–1.26]; p = 0.18 
TB or death cases  
RPT+H versus 6mH 
RR = 0.87 [95% CI: 0.54–1.39]; p = 0.54 
Adherence  
RPT+H = 95.7% 
6mH = 83.8% 
Severe adverse 
events 
RPT+H = 8.7%; 6mH = 15.4% (p > 0.05) 
RIF+H = 10.6%; 6mH = 15.4% (p > 0.05) 
Hepatotoxicity 
RPT+H =1.5%; 6mH = 5.5% 




























Multicenter RCT (Brazil, Canada, 
USA and Spain) 
 
n = 8,053 
 
People aged > 12 years at high risk 
of LTBI progression to active 
disease 
 
Non-inferiority study  
 
33 months of follow-up 
 
 Rifapentine+isoniazid DOT for  
3 months (3HP) 1x/week 
 Isoniazid self-administered for  
9 months (9H) 1x/day 
TB cases 
Difference in rates of TB = -0.19% with 
noninferiority margin of 0.75%  
(per protocol analysis) 
Difference in rates of TB = -0.24% with 
noninferiority margin of 0.75% (modified 
intention- to- treat analysis) 
RR = 0.44 [95% CI: 0.18–1.07]  
Death cases RR = 0.75 [95% CI: 0.47–1.19]  
Adherence 
3HP = 82.1%; 9H = 69% (p < 0.001) 
RR = 1.19 [95% CI: 1.16–1.22]  
Hepatotoxicity 
3HP = 0.4%; 9H = 2.7% (p < 0.001) 
RR = 0.16 [95% CI: 0.10–0.27]  
Discontinuation 
due to an adverse 
event 
3HP = 4.9%; 9H = 3.7% (p = 0.009) 
RR = 1.32 [95% CI: 1.07–1.64]  
RCT: randomized controlled trials; HIV: human immunodeﬁ ciency virus; LTBI: latent tuberculosis infection; DOT: directly observed therapy; 
TB: tuberculosis; RPT+H: rifapentine+isoniazid; 6mH: isoniazid for 6 months; 6yH: isoniazid up to 6 years; RR: relative risk; CI: conﬁ dence interval; 
RIF+H: rifamicin+isoniazid; USA: United States of America; 3HP: rifapentine+isoniazid for 3 months; 9H: isoniazid for 9 months.
International recommendations - The recommendations 
from the clinical guidelines and evidence-based synopsis 
about LTBI treatment are shown in Table 3. Treatments with 
and without rifapentine were reviewed to guide the update of 
the Brazilian recommendation. We found that clinical guidelines 
available until 2011(4) (16) (17) did not recommended the use of 
rifapentine for LTBI chemoprophylaxis; the year in which the 
results of both RCTs(11) (12) herein presented were published.
Since 2012, guidelines started to cite rifapentine for 
prevention. The evidence-based synopsis of the Centers for 
Disease Control and Prevention (CDC), United States fo 
America(13), recommends isoniazid + rifapentine combination 
for 3 months under DOT for the general population and 
healthy HIV-positive patients. The recommendation was 
based on both RCTs reviewed in this summary study(11) (12) and 
on a third RCT, which was excluded because it was a phase 
II design and its comparator was different from isoniazid(19).
Despite considering the same RCTs, the guidelines from 
the National Institutes of Health (NIH) of the United States 
Vidal JS et al. - Rifapentine for latent tuberculosis infection
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TABLE 3 - Recommendations for LTBI treatment from clinical guidelines and evidence-based synopsis that rejected the hypothesis of 
active tuberculosis.
Locality, year Population Recommendation 
WHO, 2011(4) 
Adults and adolescents 
with HIV in resource-
limited settings 
Isoniazid (300mg/day) for 6 months (applies to pregnant 
women and patients on ART)  
Regimens with pyrazinamide, rifampin, or rifapentine are as 
effective as isoniazid, but with higher rates of toxicity 
Children with HIV in 
resource-limited settings 
Isoniazid (10 mg/kg/day) for 6 months for children aged > 12 
years unexposed of TB. In children aged < 12 years, the 
regimen is only indicated if they are exposed to TB cases. 
UK, 2011(16) 
Adults with HIV in an 
area of low TB prevalence 
Isoniazid for 6 months or  
Rifampicin + isoniazid (300mg/day) for 3 months or  
Rifampicin + isoniazid (900mg/week) for 3 months or  
Rifampicin for 4 months 
UK, 2011(17) 
With HIV: any age and 
TT ≥ 6mm without BCG 
or TT ≥ 15mm with BCG 
Isoniazid for 6 months or  
Rifampicin for 6 months, if up to 35 years of age and contact 
with isoniazid-resistant TB case 
No HIV: up to 35 years 
and ≥ 6mm without BCG 
or TT ≥ 15 mm with BCG 
Isoniazid for 6 months or  
Rifampicin + isoniazid for 3 months 
CDC, 2012(13) 
Age > 12 years, with or 
without HIV, healthy and 
without ART 
Rifapentine + isoniazid (maximum 900mg each) once a week 
for 3 months under DOT 
Australia, 2012(18) 
With and without HIV, 
any age and pregnant 
Isoniazid (300 mg/day) for 9 months (first line and pregnant 
women) 
Rifampicin for 4 months (alternative)  
Rifapentine without registration in Australia 
USA,    2012a    (14) 
Adults with HIV, testing 
positive for LTBI and 
adults with HIV exposed 
to TB cases regardless of 
the outcome for LTBI 
Isoniazid (300mg/day) for 9 months  
Isoniazid (900mg/2× week DOT) for 9 months.  
Recommend daily rifampin or rifabutin monotherapy for 4 
months, but with dose adjustment if there is concomitant use of 
ART 
Not recommend rifapentine + isoniazid for 3 months: risk of 
interacting with ART 
Not recommend rifampicin + pyrazinamide for 2 months: risk 
of fatal hepatotoxicity 
USA, 2012b(15) 
Children 2-11 years with 
HIV, exposed to TB cases 
with positive TT 
Isoniazid (10–15mg/kg/1× day) for 9 months or  
Isoniazid (20–30mg/kg/2× day) for 9 months with DOT by 
trained professional, if adherence cannot be guaranteed by 
parents or family members  
Rifampicin for 6 months, if exposed to TB resistant to isoniazid 
Rifapentine + isoniazid not recommended for patients aged < 2 
LTBI: latent tuberculosis infection; TB: tuberculosis; WHO: World Health Organization; UK: United Kingdom; CDC: Centers for Disease Control 
and Prevention; USA: United States of America; HIV: human immunodeﬁ ciency virus; TT: tuberculin test; BCG: Bacillus Calmette-Guérin vaccine; 
ART: antiretroviral therapy; DOT: directly observed therapy. Note: USA guidelines (2012) recommend the administration of isoniazid associated with pyridoxine (25mg).
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fo America(14) (15) recommend isoniazid monotherapy for LTBI 
chemoprophylaxis for the general population and HIV-positive 
patients, including adults and children.
The studies analyzed indicated that thus far, rifapentine + 
isoniazid combination treatment for 3 months is neither inferior 
nor superior to isoniazid monotherapy for 6 or 9 months, in the 
prevention of mortality or progression of LTBI to TB in the 
general population and HIV-positive patients. This result may 
indicate that there is some equivalence between the combination 
therapy and monotherapy. 
The strongest evidence for this was obtained from a non-
multicenter, non-blinded study(11). Although blinding is largely 
known as a commandment in RCT, it does not represent an absolute 
absence of bias: participants’ beliefs about allocation may have 
a role in biased results(20). In both the selected RCTs(11) (12), the 
intervention arms of rifapentine + isoniazid combination involved 
DOT, which has beneﬁ ted the adherence in these groups and 
indicates a successful strategy to guarantee treatment effectiveness.
The RCT that was excluded in the selection of studies was 
conducted in Brazil(19). Although the sample representativeness 
for the Brazilian setting, the study was a phase II design study 
and compared rifapentine to the rifampin + pyrazinamide 
combination, which is not recommended by the Brazilian National 
Tuberculosis Control Program for LTBI control in Brazil. 
Although pharmacokinetic studies were excluded to gather 
the ﬁ ndings on the efﬁ cacy, these studies highlighted that 
rifamycins are cytochrome P450 enzyme complex inducers, and 
this characteristc may contribute to a reduction in the efﬁ cacy 
of protease inhibitors in HIV-positive patients, especially those 
under antiretroviral therapy(6). The exclusion of patients under 
antiretroviral therapy in both RCTs(11) (12) represents a limitation 
of the results, since there is a signiﬁ cant population outside 
the controlled conditions that will be exposed to this drug 
interaction. Thus, future studies on patients with HIV/acquired 
immunodeﬁ ciency virus under antiretroviral therapy are needed. 
Many studies involving patients at high risk of progression 
of LTBI to active TB have been conducted. A systematic review 
investigated treatments for LTBI in HIV-positive patients, but 
did not explore the use of rifapentine(21). In another database 
(ClinicalTrials.gov), there were registrations from two ongoing 
clinical studies that may provide more information about the 
effectiveness and safety of isoniazid + rifapentine combination. One 
of them (NCT00023452) was a continuation of the RCT by Sterling 
et al(12), and the other (NCT01404312) is still in the recruitment 
phase; the latter RCT is an open-label study and compares the 
beneﬁ ts of the 4-week isoniazid + rifapentine combination therapy 
to the 9-month isoniazid monotherapy in HIV-infected persons. 
Although a few studies on the effectiveness of rifapentine 
therapy have been published, it has been internationally 
recommended for LTBI chemoprophylaxis. The CDC 
recommends rifapentine + isoniazid combination for 3 months(13) 
based on the same evidence shown in this study.
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In conclusion, the studies included to support the decision 
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chemoprophylaxis were of moderate methodological quality 
and point to a probable equivalent efﬁ cacy in comparison to 
isoniazid monotherapy. Monitoring is recommended due to the 
risk and variance in hepatotoxicity ﬁ ndings, as well as dosage 
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